

Done		Value Indicators:	EUR	Warburg ESG Risk Score:	2.7	Description:	
Buy		DCF:	189.00	ESG Score (MSCI based):	2.0	Custom software and digital	
400.00				Balance Sheet Score:	4.0	engineering	
EUR 190.00				Market Liquidity Score:	2.0	3 3	
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2023e
		Market cap:	1,050.8	Freefloat	70.30 %	Beta:	1.1
Price	EUR 76.35	No. of shares (m):	13.8	Carl G. Duerschmidt	20.00 %	Price / Book:	5.7 x
Upside	148.9 %	EV:	1,145.9	Detlef Dinsel	9.70 %	Equity Ratio:	30 %
		Freefloat MC:	738.7			Net Fin. Debt / EBITDA:	1.3 x
		Ø Trad. Vol. (30d):	1.26 m			Net Debt / EBITDA:	1.3 x


Preliminary results back estimates; Cross-reads suggest improvement in H2

- Nagarro has released its preliminary financial results. In 2023, revenues reached EUR 912m. The company's latest target was a revenue level of EUR 915m. Our projections were at EUR 925m. Nagarro recorded adj. EBITDA of EUR 125.9m which is in line with our estimate of EUR 125.8m. At the end of 2023, the cash balance was EUR 109m compared to EUR 110m at the end of 2022 suggesting an improvement in free cash flow generation.
- Nagarro's results reflect that Q4 had fewer working days than Q4/22. The 2024 guidance had already been published. Nagarro's management targets revenue in the region of EUR 1bn at constant currencies. The adjusted EBITDA margin is forecast to reach 14%. These targets are approximately in line with our assumptions, confirming the investment case.

Nagarro is scheduled to publish its annual report on April 16. In this context, management might make further comments on the current business environment. Some internationally active IT services companies have already reported their results and outlined their expectations for 2024.

- Capgemini, for example, expects an improvement in the US to start in Q2 2024, with a reacceleration in H2 2024. The US market and the financial-services vertical impeded Nagarro's revenue growth during the course of 2023. M&A activity may increase as valuations become more reasonable and potential for value creation increases. Headcount growth will occur throughout the year to support a strong top-line performance in the final quarter, setting the stage for a positive 2025. Investment is being made in AI solutions and platforms, with larger investments likely in H2 2024 and primarily 2025.
- Cognizant highlighted its focus on larger deals in 2023 with large deal wins contributing more to 2024 and creating a backlog for the future. At the same time, management admitted that discretionary spend in 2024 remains unknown and provides upside for its revenue growth targets.
- It its Q2 call, **Endava** highlighted that clients are seeking diversified delivery, including cost-effective capabilities from India and Southeast Asia. Despite the need for diversified delivery locations, pricing trends have remained stable. The company is carrying out a business optimization programme and expects its upcoming quarter to be the margin trough. While client budgets have increased, spending has not yet followed suit. At the same time, management has seen signs of easing in February.
- EPAM expressed its confidence in H2/24 due to increased client activities and a backlog of delayed projects. Profitability is also expected to improve in H2. Epam's confidence is underpinned by salary increases, which are planned for Q2 2024, alongside significant investments in Al. Management highlighted that demand is stabilizing and strong traction is anticipated, especially in life sciences and energy sectors. Headcount growth is expected especially in India and Latin America. While pricing structures are being carefully reviewed, management is avoiding multi-year commitments that could lock in rates. More fixed-fee engagements are being pursued for better profitability control.

Conclusion: The achievement of the full-year targets, the confirmation of the 2024 targets, and indication of a solid 2024 FCF are supportive for the investment case. At the same time, insights from competitor updates suggest a stabilisation of the market environment and improvement in the second half of the year. **Buy rating and PT of EUR 190 are reiterated.**




Rel. Performance vs SDAX:	
1 month:	-14.4 %
6 months:	8.9 %
Year to date:	-12.8 %
Trailing 12 months:	-22.8 %

Company events:	
16.04.24	FY 2023
14.05.24	Q1
14.08.24	Q2
14.11.24	Q3

FY End: 31.12. in EUR m	CAGR (22-25e)	2019	2020	2021	2022	2023e	2024e	2025e
Sales	12.6 %	402.4	430.4	546.0	856.3	912.0	1,017.5	1,221.0
Change Sales yoy		40.1 %	6.9 %	26.9 %	56.8 %	6.5 %	11.6 %	20.0 %
gross margin		32.1 %	32.6 %	28.3 %	28.9 %	30.5 %	30.2 %	29.9 %
(company reporting)								
EBITDA adj.		55.0	76.2	79.7	148.5	125.9	154.6	187.9
Margin		13.7 %	17.7 %	14.6 %	17.3 %	13.8 %	15.2 %	15.4 %
EBITDA	6.9 %	61.6	66.2	70.3	145.6	117.9	145.6	177.9
Margin		15.3 %	15.4 %	12.9 %	17.0 %	12.9 %	14.3 %	14.6 %
EBIT	6.8 %	42.4	44.5	45.7	112.4	85.1	110.6	136.8
Margin		10.5 %	10.3 %	8.4 %	13.1 %	9.3 %	10.9 %	11.2 %
Net income before minorities		30.4	24.4	30.0	77.3	56.4	74.8	94.2
Net income	6.8 %	25.5	18.4	30.0	77.3	56.4	74.8	94.2
EPS	7.0 %	n.a.	1.62	2.51	5.58	4.10	5.43	6.84
FCFPS		2.00	4.48	1.81	3.95	5.35	4.58	5.04
FCF / Market cap		n.a.	5.3 %	1.5 %	3.2 %	7.0 %	6.0 %	6.6 %
EV / Sales		n.a.	2.5 x	3.0 x	2.1 x	1.3 x	1.1 x	0.9 x
EV / EBIT adj.		n.a.	22.0 x	33.8 x	15.6 x	13.4 x	10.0 x	7.7 x
EV / EBIT		n.a.	23.8 x	35.4 x	16.4 x	14.2 x	10.4 x	7.9 x
P / E		n.a.	52.6 x	48.9 x	21.8 x	18.6 x	14.1 x	11.2 x
Net Debt		86.0	87.8	149.7	155.8	157.2	95.1	26.7
ROCE (NOPAT)		23.0 %	20.5 %	18.8 %	30.2 %	18.4 %	22.5 %	26.3 %
Guidance:	2023: revenue	: EUR 915m	; adj. EBITD <i>i</i>	A margin։ app	orox. 13%			






Company Background

- Nagarro provides technology and custom software development services for digital transformation,...
- ...with a focus on disruptive technologies such as artificial intelligence, big data, and internet of things.
- Complementary business fields such as managed services, e-commerce solutions or ERP consulting complete the offering.
- While the majority of revenue is generated in higher price countries, Nagarro is able to serve this demand with access to experts in regions associated with lower costs.

Competitive Quality

- Nagarro is a trusted and valued digitalisation partner developing tailor-made software to achieve competitive differentiation for its clients.
- Technological focus and expertise position the company as an IT engineering expert rather than a consulting or services company.
- Proprietary software Ginger supports collaboration, a decentralised organisational structure which provides access to IT talent and enables Nagarro to serve both, small and large companies around the globe.
- Organizational design and processes allow Nagarro to cross-fertilize knowledge across the global organisation and adapt quickly to new technologies and client needs with lean and agile teams and short time-to-market.
- Access to scarce IT specialists: Nagarro's > 17,000 IT experts e.g. in India, China or Romania have a strong footprint in future-oriented technologies such as cloud, AI, IoT, deep learning or big data.





DCF model														
	Detaile	d forecas	t period				-	Γransitior	al period					Term. Value
Figures in EUR m	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	
Sales	912.0	1,017.5	1,221.0	1,453.0	1,712.5	2,000.0	2,315.6	2,659.1	3,029.9	3,427.1	3,849.3	4,295.1	4,381.0	
Sales change	6.5 %	11.6 %	20.0 %	19.0 %	17.9 %	16.8 %	15.8 %	14.8 %	13.9 %	13.1 %	12.3 %	11.6 %	2.0 %	2.0 %
EBIT	85.1	110.6	136.8	159.8	179.8	210.0	243.1	279.2	318.1	359.8	404.2	451.0	460.0	
EBIT-margin	9.3 %	10.9 %	11.2 %	11.0 %	10.5 %	10.5 %	10.5 %	10.5 %	10.5 %	10.5 %	10.5 %	10.5 %	10.5 %	
Tax rate (EBT)	28.0 %	28.0 %	28.0 %	32.0 %	32.0 %	32.0 %	32.0 %	32.0 %	32.0 %	32.0 %	32.0 %	32.0 %	32.0 %	
NOPAT	61.3	79.7	98.5	108.7	122.3	142.8	165.3	189.9	216.3	244.7	274.8	306.7	312.8	
Depreciation	32.7	35.0	41.1	16.0	17.1	20.0	23.2	26.6	30.3	34.3	38.5	43.0	48.2	
in % of Sales	3.6 %	3.4 %	3.4 %	1.1 %	1.0 %	1.0 %	1.0 %	1.0 %	1.0 %	1.0 %	1.0 %	1.0 %	1.1 %	
Changes in provisions	-4.9	1.0	1.0	1.9	2.1	2.4	2.6	2.8	3.0	3.3	3.5	3.7	0.7	
Change in Liquidity from														
- Working Capital	-23.1	12.2	23.5	77.4	38.9	43.1	47.3	51.5	55.6	59.6	63.3	66.9	12.9	
- Capex	7.0	7.7	9.0	16.0	18.8	22.0	25.5	29.3	33.3	37.7	42.3	47.2	48.2	
Capex in % of Sales	0.8 %	0.8 %	0.7 %	1.1 %	1.1 %	1.1 %	1.1 %	1.1 %	1.1 %	1.1 %	1.1 %	1.1 %	1.1 %	
- Other	25.0	27.9	33.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	80.3	67.9	74.6	33.2	83.8	100.0	118.3	138.5	160.7	184.9	211.1	239.2	300.6	307
PV of FCF	80.3	62.6	63.5	26.1	60.6	66.8	72.8	78.6	84.2	89.3	94.0	98.3	113.9	1,809
share of PVs		7.37 %						28.0	2 %					64.61 %

Model parameter				Valuation (m)			
Derivation of WACC:		Derivation of Beta:		Present values 2035e	991		
				Terminal Value	1,809		
Debt ratio	9.00 %	Financial Strength	1.14	Financial liabilities	253		
Cost of debt (after tax)	2.4 %	Liquidity (share)	1.14	Pension liabilities	13		
Market return	8.25 %	Cyclicality	1.14	Hybrid capital	0		
Risk free rate	2.75 %	Transparency	1.14	Minority interest	0		
		Others	1.14	Market val. of investments	0		
				Liquidity	60	No. of shares (m)	13.8
WACC	8.42 %	Beta	1.14	Equity Value	2,594	Value per share (EUR)	188.51

Selis	ilivity va	liue per Sili	are (EUK)													
		Terminal C	Growth								Delta EBIT	-margin					
Beta	WACC	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.34	9.4 %	145.29	148.21	151.32	154.64	158.19	162.00	166.10	1.34	9.4 %	126.89	136.14	145.39	154.64	163.90	173.15	182.40
1.24	8.9 %	158.99	162.50	166.25	170.27	174.59	179.25	184.29	1.24	8.9 %	140.11	150.17	160.22	170.27	180.32	190.37	200.43
1.19	8.7 %	166.59	170.45	174.58	179.03	183.82	189.00	194.61	1.19	8.7 %	147.53	158.03	168.53	179.03	189.52	200.02	210.52
1.14	8.4 %	174.76	179.01	183.58	188.51	193.83	199.61	205.89	1.14	8.4 %	155.56	166.54	177.53	188.51	199.49	210.47	221.46
1.09	8.2 %	183.58	188.27	193.34	198.81	204.75	211.21	218.26	1.09	8.2 %	164.29	175.80	187.30	198.81	210.32	221.82	233.33
1.04	7.9 %	193.10	198.30	203.93	210.03	216.68	223.93	231.88	1.04	7.9 %	173.80	185.88	197.96	210.03	222.11	234.19	246.26
0.94	7.4 %	214.62	221.08	228.10	235.77	244.18	253.44	263.70	0.94	7.4 %	195.62	209.01	222.39	235.77	249.15	262.53	275.91

- Slight EBIT margin expansion anticipated
- Other: IFRS 16 impact in the detailed forecast. Depreciation and capex at same levels thereafter.

Nagarro



Valuation							
	2019	2020	2021	2022	2023e	2024e	2025e
Price / Book	n.a.	22.2 x	15.2 x	10.2 x	5.7 x	4.0 x	3.1 x
Book value per share ex intangibles	n.a.	-5.54	-5.90	-3.85	-4.90	0.54	6.39
EV / Sales	n.a.	2.5 x	3.0 x	2.1 x	1.3 x	1.1 x	0.9 x
EV / EBITDA	n.a.	16.0 x	23.0 x	12.6 x	10.2 x	7.9 x	6.1 x
EV / EBIT	n.a.	23.8 x	35.4 x	16.4 x	14.2 x	10.4 x	7.9 x
EV / EBIT adj.*	n.a.	22.0 x	33.8 x	15.6 x	13.4 x	10.0 x	7.7 x
P/FCF	n.a.	19.0 x	67.9 x	30.8 x	14.3 x	16.7 x	15.1 x
P/E	n.a.	52.6 x	48.9 x	21.8 x	18.6 x	14.1 x	11.2 x
P / E adj.*	n.a.	52.6 x	48.9 x	21.8 x	18.6 x	14.1 x	11.2 x
Dividend Yield	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
FCF Potential Yield (on market EV)	n.a.	3.0 %	2.5 %	5.1 %	5.3 %	7.1 %	10.0 %
*Adjustments made for: -							


Company Specific Items							
	2019	2020	2021	2022	2023e	2024e	2025e
gross profit (company reporting)	129.1	140.2	154.4	247.1	278.4	307.5	365.1
gross margin (company reporting)	32.1 %	32.6 %	28.3 %	28.9 %	30.5 %	30.2 %	29.9 %



Consolidated profit & loss							
In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Sales	402.4	430.4	546.0	856.3	912.0	1,017.5	1,221.0
Change Sales yoy	40.1 %	6.9 %	26.9 %	56.8 %	6.5 %	11.6 %	20.0 %
Increase / decrease in inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Own work capitalised	0.9	0.3	0.2	0.3	1.9	2.2	2.5
Material expenses	49.1	49.2	59.1	77.0	85.6	119.0	146.5
Personnel expenses	254.7	271.7	373.0	571.1	641.2	646.1	769.2
Other operating income	12.7	11.6	14.8	28.2	25.0	9.0	10.0
Other operating expenses	49.8	53.3	55.5	89.0	88.8	111.9	134.3
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	61.6	66.2	70.3	145.6	117.9	145.6	177.9
Margin	15.3 %	15.4 %	12.9 %	17.0 %	12.9 %	14.3 %	14.6 %
Depreciation of fixed assets	15.7	16.9	19.9	25.5	27.1	30.3	36.3
EBITA	45.9	49.3	50.3	120.1	90.7	115.3	141.6
Amortisation of intangible assets	3.5	4.7	4.7	7.6	5.6	4.7	4.8
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	42.4	44.5	45.7	112.4	85.1	110.6	136.8
Margin	10.5 %	10.3 %	8.4 %	13.1 %	9.3 %	10.9 %	11.2 %
EBIT adj.	45.4	48.0	47.8	117.8	90.1	114.6	140.8
Interest income	0.2	0.5	0.4	0.5	0.2	0.2	0.0
Interest expenses	5.5	7.3	7.8	11.2	7.0	7.0	6.0
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	37.2	37.7	38.2	101.7	78.3	103.8	130.8
Margin	9.2 %	8.8 %	7.0 %	11.9 %	8.6 %	10.2 %	10.7 %
Total taxes	6.8	13.4	8.2	24.4	21.9	29.1	36.6
Net income from continuing operations	30.4	24.4	30.0	77.3	56.4	74.8	94.2
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	30.4	24.4	30.0	77.3	56.4	74.8	94.2
Minority interest	4.9	5.9	0.0	0.0	0.0	0.0	0.0
Net income	25.5	18.4	30.0	77.3	56.4	74.8	94.2
Margin	6.3 %	4.3 %	5.5 %	9.0 %	6.2 %	7.3 %	7.7 %
Number of shares, average	n.a.	11.4	12.0	13.8	13.8	13.8	13.8
EPS	n.a.	1.62	2.51	5.58	4.10	5.43	6.84
EPS adj.	n.a.	1.62	2.51	5.58	4.10	5.43	6.84
*Adjustments made for:							

Guidance: 2023: revenue: EUR 915m; adj. EBITDA margin: approx. 13%


Financial Ratios							
	2019	2020	2021	2022	2023e	2024e	2025e
Total Operating Costs / Sales	84.9 %	84.7 %	87.2 %	83.0 %	87.3 %	85.9 %	85.6 %
Operating Leverage	3.2 x	0.7 x	0.1 x	2.6 x	-3.7 x	2.6 x	1.2 x
EBITDA / Interest expenses	11.2 x	9.1 x	9.0 x	13.0 x	16.8 x	20.8 x	29.7 x
Tax rate (EBT)	18.2 %	35.5 %	21.5 %	24.0 %	28.0 %	28.0 %	28.0 %
Dividend Payout Ratio	n.a.	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Sales per Employee	n.a.						





Consolidated balance sheet							
In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Assets							
Goodwill and other intangible assets	111.4	106.9	178.7	217.4	253.3	253.2	253.1
thereof other intangible assets	9.0	11.0	14.0	13.6	13.3	13.2	13.1
thereof Goodwill	102.4	95.9	163.4	202.6	240.0	240.0	240.0
Property, plant and equipment	7.2	6.4	11.1	11.4	14.8	18.5	22.9
Financial assets	2.7	3.0	3.7	4.0	4.0	4.0	4.0
Other long-term assets	54.9	51.7	59.3	52.3	55.4	62.3	75.5
Fixed assets	176.2	168.0	253.0	285.1	327.6	338.0	355.6
Inventories	0.0	0.1	0.3	0.3	0.3	0.4	0.5
Accounts receivable	80.3	73.9	103.3	156.8	174.9	195.1	234.2
Liquid assets	43.8	107.7	106.6	110.2	67.3	130.4	199.8
Other short-term assets	41.7	37.1	61.7	65.8	66.0	77.0	84.0
Current assets	165.8	218.8	271.9	333.0	308.5	402.9	518.5
Total Assets	342.0	386.8	524.9	618.1	636.1	740.9	874.2
Liabilities and shareholders' equity							
Shareholders' equity	50.2	43.8	96.8	164.7	185.9	260.7	341.0
Minority interest	9.7	2.7	0.0	0.0	4.0	5.0	20.0
Total equity	59.9	46.5	96.8	164.7	189.9	265.7	361.0
Provisions	25.5	33.2	45.3	55.8	40.0	43.0	46.0
thereof provisions for pensions and similar obligations	4.4	6.0	10.1	12.9	8.0	9.0	10.0
Financial liabilities (total)	125.3	189.5	246.1	253.1	216.5	216.5	216.5
Short-term financial liabilities	5.3	14.4	23.8	11.5	11.5	11.5	11.5
Accounts payable	16.1	22.2	18.5	15.3	47.5	53.0	63.6
Other liabilities	115.1	95.4	118.2	129.3	142.2	162.7	187.1
Liabilities	282.0	340.3	428.0	453.5	446.3	475.3	513.2
Total liabilities and shareholders' equity	342.0	386.8	524.9	618.1	636.1	740.9	874.2


Financial Ratios							
	2019	2020	2021	2022	2023e	2024e	2025e
Efficiency of Capital Employment							
Operating Assets Turnover	6.3 x	8.8 x	6.3 x	6.1 x	7.6 x	7.5 x	7.5 x
Capital Employed Turnover	2.8 x	3.2 x	2.2 x	2.7 x	2.6 x	2.8 x	3.1 x
ROA	14.5 %	11.0 %	11.9 %	27.1 %	17.2 %	22.1 %	26.5 %
Return on Capital							
ROCE (NOPAT)	23.0 %	20.5 %	18.8 %	30.2 %	18.4 %	22.5 %	26.3 %
ROE	40.8 %	39.2 %	42.7 %	59.1 %	32.2 %	33.5 %	31.3 %
Adj. ROE	40.8 %	39.2 %	42.7 %	59.1 %	32.2 %	33.5 %	31.3 %
Balance sheet quality							
Net Debt	86.0	87.8	149.7	155.8	157.2	95.1	26.7
Net Financial Debt	81.6	81.8	139.5	142.9	149.2	86.1	16.7
Net Gearing	143.4 %	188.7 %	154.6 %	94.6 %	82.8 %	35.8 %	7.4 %
Net Fin. Debt / EBITDA	132.4 %	123.6 %	198.6 %	98.2 %	126.6 %	59.1 %	9.4 %
Book Value / Share	n.a.	3.8	7.0	12.0	13.5	18.9	24.8
Book value per share ex intangibles	n.a.	-5.5	-5.9	-3.9	-4.9	0.5	6.4





Consolidated cash flow statement							
In EUR m	2019	2020	2021	2022	2023e	2024e	2025e
Net income	30.4	24.4	30.0	77.3	56.4	74.8	94.2
Depreciation of fixed assets	15.7	16.9	19.9	25.5	27.1	30.3	36.3
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	3.5	4.7	4.7	7.6	5.6	4.7	4.8
Increase/decrease in long-term provisions	0.4	1.2	1.3	1.9	-4.9	1.0	1.0
Other non-cash income and expenses	-2.9	6.6	8.7	18.4	0.0	0.0	0.0
Cash Flow before NWC change	47.1	53.8	64.5	130.7	84.3	110.7	136.3
Increase / decrease in inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in accounts receivable	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in accounts payable	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in other working capital positions	-6.3	18.4	-20.6	-48.4	21.4	-12.1	-24.4
Increase / decrease in working capital (total)	-6.3	18.4	-20.6	-48.4	21.4	-12.1	-24.4
Net cash provided by operating activities [1]	40.9	72.2	44.0	82.3	105.6	98.7	111.9
Investments in intangible assets	-1.3	-1.0	-0.8	-0.6	-1.5	-1.6	-1.7
Investments in property, plant and equipment	-1.8	-2.6	-1.9	-3.5	-5.5	-6.1	-7.3
Payments for acquisitions	-2.9	-7.8	-50.1	-40.4	-50.0	0.0	0.0
Financial investments	-2.5	1.2	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.4	0.1	0.0	0.1	0.0	0.0	0.0
Net cash provided by investing activities [2]	-8.0	-10.1	-52.8	-44.5	-57.0	-7.7	-9.0
Change in financial liabilities	-3.3	23.9	18.2	11.4	-36.5	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Purchase of own shares	0.0	0.0	0.0	-10.0	-30.0	0.0	0.0
Capital measures	0.0	0.1	6.1	0.0	0.0	0.0	0.0
Other	-13.8	-17.5	-24.2	-29.7	-25.0	-27.9	-33.5
Net cash provided by financing activities [3]	-17.1	6.5	0.0	-28.3	-91.5	-27.9	-33.5
Change in liquid funds [1]+[2]+[3]	15.7	68.6	-8.8	9.5	-42.8	63.1	69.4
Effects of exchange-rate changes on cash	0.4	-1.4	0.6	-1.3	0.0	0.0	0.0
Cash and cash equivalent at end of period	44.0	110.9	99.6	114.8	67.3	130.4	199.8

Financial Ratios							
	2019	2020	2021	2022	2023e	2024e	2025e
Cash Flow							
FCF	22.8	51.0	21.6	54.7	73.7	63.1	69.4
Free Cash Flow / Sales	5.7 %	11.9 %	4.0 %	6.4 %	8.1 %	6.2 %	5.7 %
Free Cash Flow Potential	51.7	31.6	39.7	93.6	64.0	81.0	107.9
Free Cash Flow / Net Profit	89.4 %	276.6 %	72.1 %	70.7 %	130.7 %	84.4 %	73.7 %
Interest Received / Avg. Cash	0.6 %	0.7 %	0.4 %	0.5 %	0.2 %	0.2 %	0.0 %
Interest Paid / Avg. Debt	5.0 %	4.6 %	3.6 %	4.5 %	3.0 %	3.2 %	2.8 %
Management of Funds							
Investment ratio	0.8 %	0.8 %	0.5 %	0.5 %	0.8 %	0.8 %	0.7 %
Maint. Capex / Sales	0.8 %	0.8 %	0.5 %	0.5 %	0.8 %	0.8 %	0.0 %
Capex / Dep	16.1 %	16.5 %	10.9 %	12.5 %	21.3 %	22.0 %	21.9 %
Avg. Working Capital / Sales	13.6 %	11.5 %	10.8 %	11.9 %	12.8 %	10.9 %	10.6 %
Trade Debtors / Trade Creditors	500.3 %	332.8 %	559.6 %	1028.2 %	368.2 %	368.1 %	368.2 %
Inventory Turnover	5452.4 x	387.1 x	219.6 x	291.6 x	285.2 x	297.6 x	293.0 x
Receivables collection period (days)	73	63	69	67	70	70	70
Payables payment period (days)	119	165	114	72	203	162	158
Cash conversion cycle (Days)	-103	-172	-102	-70	-229	-169	-163



Source: Warburg Research Source: Warburg Research Source: Warburg Research



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The Warburg ESG Risk Score is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold -1a share of more than 5% of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the management of a consortium for an issue in -2the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of the investment -3recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide investment banking and/or investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of confidential business information.
- The company compiling the analysis or an affiliated company had reached an agreement on the compilation of the investment -5recommendation with the analysed company.
- Warburg Research, or an affiliated company, holds a net long position of more than 0.5% of the total issued share capital of the analysed -6acompany.
- Warburg Research, or an affiliated company, holds a net short position of more than 0.5% of the total issued share capital of the analysed -6bcompany.
- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company. -6c-
- The company preparing the analysis as well as its affiliated companies and employees have other important interests in relation to the -7analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Nagarro	5	https://www.mmwarburg.com/disclaimer/disclaimer en/DE000A3H2200.htm



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEA	RCH GMBH – ANALY	SED RESEARCH UNI	VERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	149	71
Hold	47	22
Sell	8	4
Rating suspended	7	3
Total	211	100

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	48	83
Hold	7	12
Sell	0	0
Rating suspended	3	5
Total	58	100

PRICE AND RATING HISTORY NAGARRO AS OF 14.03.2024



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



FOURTIES			
EQUITIES Matthias Rode	+49 40 3282-2678		
Head of Equities	mrode@mmwarburg.com		
RESEARCH			
Michael Heider Head of Research	+49 40 309537-280	Hannes Müller Software, IT	+49 40 309537-255
Henner Rüschmeier	mheider@warburg-research.com +49 40 309537-270	Andreas Pläsier	hmueller@warburg-research.com +49 40 309537-246
Head of Research	hrueschmeier@warburg-research.com	Banks, Financial Services	aplaesier@warburg-research.com
Stefan Augustin Cap. Goods, Engineering	+49 40 309537-168 saugustin@warburg-research.com	Malte Schaumann Technology	+49 40 309537-170 mschaumann@warburg-research.com
Jan Bauer	+49 40 309537-155	Oliver Schwarz	+49 40 309537-250
Renewables Christian Cohrs	jbauer@warburg-research.com +49 40 309537-175	Chemicals, Agriculture Simon Stippig	oschwarz@warburg-research.com +49 40 309537-265
Industrials & Transportation	ccohrs@warburg-research.com	Real Estate, Telco	sstippig@warburg-research.com
Dr. Christian Ehmann BioTech, Life Science	+49 40 309537-167 cehmann@warburg-research.com	Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com
Felix Ellmann	+49 40 309537-120	Robert-Jan van der Horst	+49 40 309537-290
Software, IT	fellmann@warburg-research.com	Technology	rvanderhorst@warburg-research.com
Jörg Philipp Frey Retail, Consumer Goods	+49 40 309537-258 jfrey@warburg-research.com	Andreas Wolf Software, IT	+49 40 309537-140 awolf@warburg-research.com
Marius Fuhrberg Financial Services	+49 40 309537-185		
Fabio Hölscher	mfuhrberg@warburg-research.com +49 40 309537-240		
Automobiles, Car Suppliers	fhoelscher@warburg-research.com		
Philipp Kaiser Real Estate, Construction	+49 40 309537-260 pkaiser@warburg-research.com		
Thilo Kleibauer	+49 40 309537-257		
Retail, Consumer Goods	tkleibauer@warburg-research.com		
INSTITUTIONAL EQU			
Marc Niemann Head of Equity Sales, Germany	+49 40 3282-2660 mniemann@mmwarburg.com	Rudolf Alexander Michaelis Germany	+49 40 3282-2649 rmichaelis@mmwarburg.com
Tim Beckmann	+49 40 3282-2665	Roman Alexander Niklas	+49 69 5050-7412
United Kingdom	tbeckmann@mmwarburg.com +49 69 5050-7411	Switzerland	rniklas@mmwarburg.com
Lea Bogdanova United Kingdom, Ireland	lbogdanova@mmwarburg.com		
Jens Buchmüller	+49 69 5050-7415	Antonia Möller Roadshow/Marketing	+49 69 5050-7417
Scandinavia, Austria Matthias Fritsch	jbuchmueller@mmwarburg.com +49 40 3282-2696	Charlotte Wernicke	amoeller@mmwarburg.com +49 40 3282-2669
United Kingdom	mfritsch@mmwarburg.com	Roadshow/Marketing	cwernicke@mmwarburg.com
Maximilian Martin Austria, Poland	+49 69 5050-7413	Juliane Niemann Roadshow/Marketing	+49 40 3282-2694 jniemann@mmwarburg.com
SALES TRADING	mmartin@mmwarburg.com		, ,
Oliver Merckel	+49 40 3282-2634	DESIGNATED SPONSOR Marcel Magiera	+49 40 3282-2662
Head of Sales Trading	omerckel@mmwarburg.com	Designated Sponsoring	mmagiera@mmwarburg.com
Rico Müller	+49 40 3282-2685	Sebastian Schulz	+49 40 3282-2631
Sales Trading	rmueller@mmwarburg.com	Designated Sponsoring	sschulz@mmwarburg.com
Bastian Quast Sales Trading	+49 40 3282-2701 bguast@mmwarburg.com	Jörg Treptow Designated Sponsoring	+49 40 3282-2658 jtreptow@mmwarburg.com
MACRO RESEARCH	- 1		Jaspieri Gand
Carsten Klude	+49 40 3282-2572	Dr. Christian Jasperneite	+49 40 3282-2439
Macro Research	cklude@mmwarburg.com	Investment Strategy	cjasperneite@mmwarburg.com
Our research can be f	found under:		
Warburg Research	research.mmwarburg.com/en/index.html	LSEG	www.lseg.com
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		
For access please conta		10 11 10 11	
Andrea Schaper Sales Assistance	+49 40 3282-2632 aschaper@mmwarburg.com	Kerstin Muthig Sales Assistance	+49 40 3282-2703 kmuthig@mmwarburg.com
	acchaporagniinwaibaig.com	54.55 / ISS.541100	Kindang@minwarbarg.com